Publications by authors named "C Benini"

Background: Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP).

Methods: We conducted a 6-month prospective observational study on postmenopausal women with severe OP receiving treatment with romosozumab either alone (in patients naïve to treatment) or in combination with ongoing long-term denosumab (>2 years) or continuing ongoing denosumab alone (>2 years). We collected serum samples for bone turnover markers, bone modulators, and calcium phosphate metabolism at baseline, month 3 and month 6.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the effectiveness of IV neridronate for treating complex regional pain syndrome (CRPS) type I over an extended period of time, focusing on long-term outcomes and predictors of success.
  • Results showed significant reductions in pain levels and improvement in symptoms like hyperalgesia, allodynia, and loss of motion, with many patients experiencing a notable decrease in pain scores within just three months.
  • Factors influencing a better response to treatment included being male, having lower limb CRPS, absence of predisposing events, and observing early improvements in pain, highlighting the potential for tailored treatment approaches.
View Article and Find Full Text PDF

Background: Bone metabolism is disrupted in rheumatoid arthritis (RA); however, the bone metabolic signature of RA is poorly known. The objective of the study is to further characterize the bone metabolic profile of RA and compare it to psoriatic arthritis (PsA), systemic sclerosis (SSc) and healthy controls.

Methods: We did a cross-sectional case-control study on consecutively enrolled patients and age-matched controls.

View Article and Find Full Text PDF

Background: Biological DMARDs (bDMARDs) have been proven to prevent joint damage and bone erosions. Nevertheless, approximately 15% of rheumatoid arthritis (RA) patients on bDMARDs will progress despite good control of joint inflammation.

Objectives: The objective of our study is to investigate the factors associated with radiological progression of patients treated with bDMARDs.

View Article and Find Full Text PDF

Psoriatic arthritis (PsA) is an inflammatory disease characterized by peripheral and axial involvement. Biological disease-modifying antirheumatic drugs (bDMARDs) are the mainstream treatment for PsA and bDMARDs retention rate is a proxy for the drug's overall effectiveness. However, it is unclear whether IL-17 inhibitors can have a higher retention rate than tumor necrosis factor (TNF) inhibitors, in particular in axial or peripheral PsA.

View Article and Find Full Text PDF